NHS NHS
Company Profile ↓Company Overview
NHS (NHS) is a publicly traded company listed on with a market capitalization of $168.35M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 8.1.
Maintains a net profit margin of 86.2%.
Carries low leverage with a debt-to-equity ratio of 0.26.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Oct 2025 Revenue of $23.45M (-43.8% YoY); net profit $20.22M.
- Trailing 12 Months Year-on-year growth — revenue -43.8%, earnings -46.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -43.83% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -46.72% |
Stock Price Performance
| 1 Year: | -14.24% |
| 6 Months: | -7.85% |
| 3 Months: | -6.77% |
| 1 Month: | -0.14% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.68 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 86.2%.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|
| Revenue | -30.38M | 9.74M | 41.75M | 23.45M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 3.11M | 6.02M | 3.81M | 3.23M |
| Operating Income | - | - | - | - |
| EBITDA | - | - | - | - |
| Interest Expense | 1.02M | 3.14M | 3.19M | 2.74M |
| Pretax Income | -33.49M | 3.72M | 37.94M | 20.22M |
| Tax Provision | - | - | - | - |
| Net Income | -33.49M | 3.72M | 37.94M | 20.22M |
| Diluted EPS | -2.28 | 0.16 | 1.43 | 0.66 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 295.32M | 303.91M | 323.58M | 339.80M |
| Current Assets | - | - | - | - | - |
| Cash & Equivalents | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Receivables | - | 6.17M | 7.91M | 5.77M | 5.59M |
| Total Liabilities | - | 127.04M | 109.48M | 89.44M | 106.51M |
| Current Liabilities | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 45.89M | 66.00M | 43.50M | 61.00M |
| Total Equity | - | 168.28M | 194.43M | 234.14M | 233.29M |
| Shares Outstanding | - | 19.54M | 26.08M | 29.92M | 31.53M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -48.69M | -5.85M | 21.10M | 3.62M |
| Investing Cash Flow | - | - | - | - | - |
| Financing Cash Flow | - | 47.18M | 6.45M | -20.73M | -3.60M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | -48.69M | -5.85M | 21.10M | 3.62M |
| Net Change in Cash | - | -1.51M | 599.04K | 379.43K | 21.75K |
Ratios (Annual)
Figures in %.
| Metric | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | 110.2% | 38.2% | 90.9% | 86.2% |
| ROE % | -19.9% | 1.9% | 16.2% | 8.7% |
| ROCE % | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NHS
How (NHS) Movements Inform Risk Allocation Models - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQZWFtX1k3Y1FWOExOMHM0djdLWWtzRGJxZGpQX2xZbldpajVzT0RfVjNZNTZoWnZHcnVEelN0bDkwcTFkMkQtZ1g2V25XSUFUbWlDYlpxdTBtSHoyRVdBTWxQdE9wYzVyN05xd0ZFbmNYc2ppN2lDa1hOSTlncEpzaXZZNVFQbl8yb3FleE…
Fraudsters jailed for £279,000 con at Redditch hospital - BBC
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE51Tl9NWlR0WXRGUlNNclZ2MHNkSHl6V09IRlNUS1VjWnl6SHFlbC1fT3V6UTJRYnVXeDR6anp1ZTJLUzZWS0tfaUJvbEtrZmhkVU9jSFVFNGxlNnB2N0E?oc=5" target="_blank">Fraudsters jailed for £279,000 con at Re…
Zero voting power comes with First Trust's reported stake in Neuberger High Yield (NHS). - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOS3VKR3Z3Nkw0cVo3LXU5MkpNNmpIcWVlOF92SmF3YmVBY000SmN3TjJyUGJCSGE3X0ZwRU52Z1Vtdko2SHF6SWo5eG43U0dCTE9WV0V2cDJYbVZYWVd6YjJLSDZJbHpSeVp3UXVEV200b29SU3B0SXRQckE1MHZoQ0htdUJreENUandXSE…
NHS Stock Price, Quote & News - Syfe
<a href="https://news.google.com/rss/articles/CBMiSkFVX3lxTE5iZUZtSXA4ci14LUNFQms1VkNST0lyQXd3R0RpY2UzdW43bGhGRF9nX3pEdnFFd25RWUgxX2I2OUhfR0pZTXlCMnlB?oc=5" target="_blank">NHS Stock Price, Quote & News</a> <font color="#6f6f6f">…
Former NHS worker jailed for £279k fraud involving hospital stock theft - Rayo
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOQzdjTTJWQ1oyNFdVVHJ1Y0FRUE5WRzZwZjNLdm1BcjhqMEVuZ3FiYlNKenVwR01WRjlTY1N6UmdLcjhPVExFbFJlSlVIS3hJQVdHSkxvOUVBT3ZOZVVKa2ZJNFZTZ2YwdWQ5QjdvN3dMTUZhdloyaTRkUW1VcG1pU0ZXTXVoTHJoWnFWaD…
Grail Stock Skyrockets Reflecting Market Optimism for MCED Test Ahead of Expert Panel Meeting - GenomeWeb
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNVkR6bkdyeFRucEx4UGJNVkVwLS1HRzNNWnI1bnNldkZ2SllNYl9XaXVKaEp0UnRaX1NSQkRvU3lRNHRTdGNTRGszVEJCZ3NhZjZJYWxVOUgtNzBaS2dhSGFOSk9nSVBaTmFSYkVVY0F3ajVyWVJqajdXeWozOEZQWXhLTU01R1dMYUFWeX…
NHS — Frequently Asked Questions
What is the current share price of NHS?
As of 2026-10-23 16:27 PDT, NHS trades at $5.34 on NASDAQ/NYSE. Its 52-week range is $5.25 to $6.87.
What is the market capitalisation of NHS?
NHS has a market capitalisation of $168.35M on NASDAQ/NYSE.
What is the P/E ratio of NHS?
NHS trades at a trailing price-to-earnings (P/E) ratio of 8.14. Its price-to-book (P/B) ratio is 0.72.
What is the return on equity (ROE) of NHS?
NHS has a return on equity (ROE) of 8.67%.
Is NHS a good stock to buy?
This page provides a data-driven analysis of NHS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.